Biotech Industry · global
Zealand to Pay $30 Million to Partner with Generate on Multifunctional Protein Drugs for Obesity
Moving from peptides to multispecific proteins, Zealand hopes to expand its therapeutic toolkit for metabolic diseases. The collaboration bets on AI design and experimental screening capabilities; specific targets and efficacy data have not yet been disclosed.
A drug molecule capable of multiple biological actions could offer more scope for designing obesity treatments. Danish pharmaceutical company Zealand Pharma announced on October 13, 2026, that it would collaborate with Generate Biomedicines to use generative artificial intelligence to design protein drugs for obesity and other metabolic diseases, with an upfront payment of $30 million.
The collaboration initially covers two research and development programs, with an option to add a third. According to the companies’ announcements, Generate is also eligible for up to $35 million in early preclinical milestone payments; total potential milestone payments approach $1.2 billion, alongside tiered royalties based on global net sales after products reach the market. These subsequent payments depend on meeting development, regulatory and commercial conditions and cannot be regarded as realized transaction revenue.
The companies are targeting “multispecific” proteins, meaning proteins designed to recognize or act on different targets within a single molecule. For Zealand, this adds a route to exploring multiple pharmacological actions beyond its existing small-molecule and peptide research and development tools. However, the announcements have not disclosed the target combinations for the two programs, so it is not possible to assess how they would influence metabolic regulation or differ from existing therapies.
AI’s specific role in this collaboration is to help design proteins, with extensive experiments then used to test and refine those designs. Generate says its platform combines generative AI with high-throughput experimental validation to optimize candidate molecules toward predefined biological functions. This means computer-generated designs must still undergo experimental screening; the companies did not disclose model training data, design success rates, animal study results or human evidence for these two programs.
The division of development responsibilities follows this validation path: Generate will conduct research through the selection of lead drug candidates, after which Zealand will take over clinical development, regulatory submissions and global commercialization. The collaboration therefore remains at an early stage of drug discovery, and the announcements provided no timeline for entering human trials.
The deal represents a concrete commercial commitment to AI protein design and broadens Zealand’s exploration of therapies for metabolic diseases. Its medical value will ultimately depend on whether candidate molecules demonstrate the intended effects in experiments and clinical studies, and whether multiple actions can be accompanied by acceptable safety. The upfront payment establishes the starting point for the collaboration, but a series of validation steps remains before a drug can become available to patients.